SiRNA-mediated lncRNA ANRIL knockdown enhances the sensitivity of gastric cancer cells to doxorubicin

IRCMJ logo
PDF
HTML

Keywords

ANRIL
Apoptosis
Doxorubicin
Drug resistance
Gastric cancer

How to Cite

Chen, J., Dai, X., Yu, H., Pe, F., & Chen, L. (2020). SiRNA-mediated lncRNA ANRIL knockdown enhances the sensitivity of gastric cancer cells to doxorubicin. Iranian Red Crescent Medical Journal, 22(10). https://doi.org/10.32592/ircmj.2020.22.10.120

Abstract

Background: Long non-coding RNAs (lncRNAs) play pivotal roles in carcinogenesis and the development of drug resistance in various malignancies.

Objectives: The current study aimed to explore the impact of antisense non-coding RNA in the INK4 locus (ANRIL) silencing on proliferation and the sensitivity of KATO III gastric cells to the doxorubicin as a common chemotherapeutic agent.

Methods: The KATO III cells were transfected with ANRIL siRNA (si-ANRIL) using Lipofectamine™2000 reagent. Following that, the relative ANRIL levels were determined by quantitative Real-Time PCR. Trypan blue assay was conducted to observe the tumor cell proliferation following the transfection. Moreover, the MTT assay was performed to identify the cytotoxic effects of doxorubicin and si-ANRIL alone or in combination on KATO III cells. The effects of si-ANRIL/doxorubicin on KATO III cells migration and apoptosis were assessed by wound healing assay and ELISA cell death method, respectively.

Results: The results showed that the si-ANRIL significantly diminished ANRIL expression level in a time-dependent manner contributing to the distinct repression of cell growth and enhanced apoptosis. Furthermore, the si-ANRIL synergistically elevated the cytotoxic impacts of doxorubicin. Additionally, the ANRIL down-regulation dramatically promoted its induction of apoptosis. Moreover, KATO III cells transfected with si-ANRIL and exposed with doxorubicin revealed significantly reduced invasion capability and enhanced apoptosis rate.

Conclusion: These results demonstrated that the knock-down of lncRNA ANRIL could be a potential therapeutic strategy to trigger apoptosis and circumvent doxorubicin-resistance.

https://doi.org/10.32592/ircmj.2020.22.10.120
PDF
HTML

References

  1. Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WPJCm, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239-48. doi: 10.2147/CMAR.S149619. [PubMed: 29445300].
  2. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654-64. doi: 10.1016/S0140-6736(16)30354-3. [PubMed: 27156933].
  3. Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. 2017(8). doi:10.1002/14651858.CD004064.pub4.
  4. Huang T, Song C, Zheng L, Xia L, Li Y, Zhou Y. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy. 2019;18(1):62. doi: 10.1186/s12943-019-0967-5. [PubMed: 30925929].
  5. Riquelme I, Letelier P, Riffo-Campos AL, Brebi P, Roa JC. Emerging role of miRNAs in the drug resistance of gastric cancer. Int J Mol Sci. 2016;17(3):424. doi: 10.3390/ijms17030424. [PubMed: 27011182].
  6. Chen Q-n, Wei C-C, Wang Z-X, Sun M. Long non-coding RNAs in anti-cancer drug resistance. 2017;8(1):1925. doi: 10.18632/oncotarget.12461. [PubMed: 27713133].
  7. Wei L, Sun J, Zhang N, Zheng Y, Wang X, Lv L, et al. Noncoding RNAs in gastric cancer: implications for drug resistance. Mol Cancer. 2020;19(1):62. doi: 10.1186/s12943-020-01185-7. [PubMed: 32192494].
  8. Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta.2016;1859(1):169-76. doi: 10.1016/j.bbagrm.2015.06.015. [PubMed: 26149773].
  9. Hao N-B, He Y-F, Li X-Q, Wang K, Wang R-L. The role of miRNA and lncRNA in gastric cancer. Oncotarget. 2017;8(46):81572. doi: 10.18632/oncotarget.19197. [PubMed: 29113415].
  10. Wang J, Sun J, Wang J, Song Y, Gao P, Shi J, et al. Long noncoding RNAs in gastric cancer: functions and clinical applications. Onco Targets Ther. 2016;9:681-97. doi: 10.2147/OTT.S95412. [PubMed: 26929639].
  11. Congrains A, Kamide K, Ohishi M, Rakugi H. ANRIL: molecular mechanisms and implications in human health. Int J Mol Sci. 2013;14(1):1278-92. doi: 10.3390/ijms14011278. [PubMed: 23306151].
  12. Chen K-H, Chen C-H, Wallace CG, Yuen C-M, Kao G-S, Chen Y-L, et al. Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke. Oncotarget. 2016;7(46):74537-56. doi: 10.18632/oncotarget.12902. [PubMed: 27793019].
  13. Lan W-G, Xu D-H, Xu C, Ding C-L, Ning F-L, Zhou Y-L, et al. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep2016;36(1):263-70. doi: 10.3892/or.2016.4771. [PubMed: 27121324].
  14. Jiang M-C, Ni J-J, Cui W-Y, Wang B-Y, Zhuo W. Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019;9(7):1354-66. [PubMed: 31392074].
  15. Li J, Meng H, Bai Y, Wang K. Regulation of lncRNA and its role in cancer metastasis. Oncol Res. 2016;23(5):205-17. doi: 10.3727/096504016X14549667334007. [PubMed: 27098144].
  16. Evans JR, Feng FY, Chinnaiyan AM. The bright side of dark matter: lncRNAs in cancer. J Clin Invest 2016;126(8):2775-82. doi: 10.1172/JCI84421. [PubMed: 27479746].
  17. Gu Y, Chen T, Li G, Yu X, Lu Y, Wang H, et al. LncRNAs: emerging biomarkers in gastric cancer. Future Oncol. 2015;11(17):2427-41. doi: 10.2217/fon.15.175. [PubMed: 26289363].
  18. Fang X-Y, Pan H-F, Leng R-X, Ye D-Q. Long noncoding RNAs: novel insights into gastric cancer. Cancer Lett. 2015;356(2):357-66. doi: 10.1016/j.canlet.2014.11.005. [PubMed: 25444905].
  19. Liu X, Lu Y, Xu Y, Hou S, Huang J, Wang B et al. Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Lett. 2019;459:122-34. doi: 10.1016/j.canlet.2019.05.035. [PubMed: 31173853].
  20. Zhang X-w, Bu P, Liu L, Zhang X-z, Li J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun.2015;462(3):227-32. doi: 10.1016/j.bbrc.2015.04.121. [PubMed: 25956062].
  21. Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol. 2014;34(17):3182-93. doi: 10.1128/MCB.01580-13. [PubMed: 24958102].
  22. Jiang M, Huang O, Xie Z, Wu S, Zhang X, Shen A et al. A novel long non-coding RNA-ARA: adriamycin resistance associated. Biochem Pharmacol 2014;87(2):254-83. doi: 10.1016/j.bcp.2013.10.020. [PubMed: 24184505].
  23. Liu J, Wan L, Lu K, Sun M, Pan X, Zhang P et al. The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma. PLoS One .2015;10(5):e0114586. doi: 10.1371/journal.pone.0114586. [PubMed: 25992654].
  24. Kong Y, Hsieh C-H, Alonso LC. ANRIL: A lncRNA at the CDKN2A/B Locus with Roles in Cancer and Metabolic Disease. Front Endocrinol (Lausanne).2018;9:405. doi: 10.3389/fendo.2018.00405. [PubMed: 30087655].
  25. Kangarlouei R, Irani S, Noormohammadi Z, Memari F, Mirfakhraie R. ANRIL and ANRASSF1 long noncoding RNAs are upregulated in gastric cancer. J Cell Biochem. 2019;120(8):12544-8. doi: 10.1002/jcb.28520. [PubMed: 30834580].
  26. Deng W, Zhang Y, Cai J, Zhang J, Liu X, Yin J et al. LncRNA-ANRIL promotes gastric cancer progression by enhancing NF-kB signaling. Exp Biol Med (Maywood). 2019;244(12):953-9. doi: 10.1177/1535370219860207. [PubMed: 31242038].
  27. Liu P, Zhang M, Niu Q, Zhang F, Yang Y, Jiang X. Knockdown of long non-coding RNA ANRIL inhibits tumorigenesis in human gastric cancer cells via microRNA-99a-mediated down-regulation of BMI1. Braz J Med Biol Res. 2018;51(10).e6839. doi: 10.1590/1414-431X20186839. [PubMed: 30156609].